Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria

– Danicopan Phase 2 PNH combination therapy topline data expected Q4 2019 –– Initiation of Phase 3 planned for early 2020 – BLUE BELL, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Achillion...